Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

74 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Higher infection rate after 7- compared with 5-day cycle of azacitidine in patients with higher-risk myelodysplastic syndrome.
Ofran Y, Filanovsky K, Gafter-Gvili A, Vidal L, Aviv A, Gatt ME, Silbershatz I, Herishanu Y, Arad A, Tadmor T, Dally N, Nemets A, Rouvio O, Ronson A, Herzog-Tzarfati K, Akria L, Braester A, Hellmann I, Yeganeh S, Nagler A, Leiba R, Mittelman M, Merkel D. Ofran Y, et al. Among authors: hellmann i. Clin Lymphoma Myeloma Leuk. 2015 Jun;15(6):e95-9. doi: 10.1016/j.clml.2015.02.030. Epub 2015 Mar 5. Clin Lymphoma Myeloma Leuk. 2015. PMID: 25819366
Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study.
Merkel D, Filanovsky K, Gafter-Gvili A, Vidal L, Aviv A, Gatt ME, Silbershatz I, Herishanu Y, Arad A, Tadmor T, Dally N, Nemets A, Rouvio O, Ronson A, Herzog-Tzarfati K, Akria L, Braester A, Hellmann I, Yeganeh S, Nagler A, Leiba R, Mittelman M, Ofran Y. Merkel D, et al. Among authors: hellmann i. Am J Hematol. 2013 Feb;88(2):130-4. doi: 10.1002/ajh.23368. Am J Hematol. 2013. PMID: 23345248 Free article.
Prospective comparison of early bone marrow evaluation on day 5 versus day 14 of the "3 + 7" induction regimen for acute myeloid leukemia.
Ofran Y, Leiba R, Ganzel C, Saban R, Gatt M, Ram R, Arad A, Bulvik S, Hellmann I, Gino-Moor S, Zuckerman T, Hoffman R, Horowitz N, Lavi N, Ringelstein S, Henig I, Hayun M, Rowe JM. Ofran Y, et al. Among authors: hellmann i. Am J Hematol. 2015 Dec;90(12):1159-64. doi: 10.1002/ajh.24207. Epub 2015 Nov 17. Am J Hematol. 2015. PMID: 26435038 Free article.
Midostaurin in combination with intensive chemotherapy is safe and associated with improved remission rates and higher transplantation rates in first remission-a multi-center historical control study.
Berger T, Rozovski U, Moshe Y, Yaari S, Frisch A, Hellmann I, Apel A, Aviram A, Koren-Michowitz M, Yeshurun M, Ram R, Raanani P, Ofran Y, Wolach O. Berger T, et al. Among authors: hellmann i. Ann Hematol. 2019 Dec;98(12):2711-2717. doi: 10.1007/s00277-019-03795-8. Epub 2019 Sep 11. Ann Hematol. 2019. PMID: 31512015 Clinical Trial.
Bone marrow blast elimination by the fifth day of 7 + 3 induction is the strongest predictor of potential cure in patients with acute myeloid leukemia younger than 61 years of age: A long-term follow-up of a multi-center prospective study.
Ofran Y, Hayun M, Leiba R, Zuckerman T, Horowitz N, Hoffman R, Ringelstein S, Lavi N, Frisch A, Henig I, Gatt ME, Hellmann I, Arad A, Bulvik S, Ram R, Gino-Moor S, Saban R, Tvito A, Rowe JM, Ganzel C. Ofran Y, et al. Among authors: hellmann i. Am J Hematol. 2020 Jan;95(1):E3-E5. doi: 10.1002/ajh.25651. Epub 2019 Oct 17. Am J Hematol. 2020. PMID: 31591736 Free article. No abstract available.
Midostaurin in combination with chemotherapy is most effective in patients with acute myeloid leukemia presenting with high FLT3-ITD allelic ratio who proceed to allogeneic stem cell transplantation while in first complete remission.
Ofran Y, Leiba R, Frisch A, Horesh N, Henig I, Yehudai-Ofir D, Moshe Y, Neaman M, Ganzel C, Gal-Rabinovich K, Hellmann I, Weinstein V, Berger T, Wolach O. Ofran Y, et al. Among authors: hellmann i. Eur J Haematol. 2021 Jan;106(1):64-71. doi: 10.1111/ejh.13518. Epub 2020 Oct 6. Eur J Haematol. 2021. PMID: 32949053
Trial eligibility, treatment patterns and outcome for venetoclax-based therapy in AML: a prospective cohort study.
Wolach O, Levi I, Nachmias B, Tavor S, Amitai I, Ofran Y, Ganzel C, Zuckerman T, Okasha D, Hellmann I, Tadmor T, Dally N, Canaani J, Stemer G, Grunspan M, Berger AJ, Frankel N, Berelovich J, Bleterman A, Barak M, Cohen R, Moshe Y. Wolach O, et al. Among authors: hellmann i. Blood Adv. 2024 Dec 5:bloodadvances.2024014014. doi: 10.1182/bloodadvances.2024014014. Online ahead of print. Blood Adv. 2024. PMID: 39637307
Guilt and Gratitude.
Hellmann I. Hellmann I. J Clin Oncol. 2023 Feb 20;41(6):1321-1322. doi: 10.1200/JCO.22.02000. Epub 2022 Nov 22. J Clin Oncol. 2023. PMID: 36413711 No abstract available.
74 results